SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis

Mahesh M Umapathysivam; Bethany Morgan; Joshua M Inglis; Emily Meyer; Danny Liew; Venkatesan Thiruvenkatarajan; David Jesudason

doi:10.1001/jamanetworkopen.2024.2744

SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis

JAMA Netw Open. 2024 Mar 4;7(3):e242744. doi: 10.1001/jamanetworkopen.2024.2744.

Authors

Mahesh M Umapathysivam^{1

2

3

4

5}, Bethany Morgan^{2

3}, Joshua M Inglis^{2

4}, Emily Meyer^{2

3

4}, Danny Liew⁴, Venkatesan Thiruvenkatarajan⁶, David Jesudason^{2

3

4

7}

Affiliations

¹ Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia.
² Endocrine Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
³ Endocrine Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
⁴ Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
⁵ Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.
⁶ Anaesthetic Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
⁷ Basil Hetzel Institute Woodville, South Australia, Australia.

No abstract available

Plain language summary

This cohort study examines the natural history and response to treatment of sodium glucose cotransporter 2 (SGLT2) inhibitor–associated ketoacidosis compared with that of type 1 diabetes–associated ketoacidosis.

MeSH terms

Diabetes Mellitus, Type 1* / complications
Diabetes Mellitus, Type 1* / drug therapy
Diabetic Ketoacidosis* / chemically induced
Humans
Ketosis* / chemically induced
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors